Images List Premium Download Classic

Endometrial

Endometrial-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods and materials for treating endometrial cancer
Mayo Foundation For Medical Education And Research
September 14, 2017 - N°20170260571

This document provides methods and materials for detecting and/or treating endometrial hyperplasia and/or endometrial cancer. For example, this document provides methods and materials for identifying a female mammal as having endometrial hyperplasia and administering a therapy (e. G., hormone therapy) to the female mammal. For example, this document provides methods and materials for identifying a female mammal as ...
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
National Research Council Of Canada
August 17, 2017 - N°20170233487

Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also ...
Cancer therapeutics
University Of Virginia Patent Foundation
August 17, 2017 - N°20170233375

This invention relates to compounds that bind to wild-type cbfβ and inhibit cbfβ binding to runx proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type cbfβ from runx1 in cells, change occupancy of runx1 on target genes, and alter gene ...
Endometrial Patent Pack
Download + patent application PDFs
Endometrial Patent Applications
Download + Endometrial-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Endometrial-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Endometrial ablation devices and system
Hermes Innovations Llc
August 17, 2017 - N°20170231681

Systems and methods for endometrial ablation. The systems include a handle and elongated introducer sleeve extending to an expandable working end having a fluid-tight interior chamber. A thin dielectric wall surrounds at least a portion of the interior chamber and has an external surface for contacting endometrial tissue. The thin dielectric wall surrounds a collapsible-expandable frame and receives an electrically ...
Method and apparatus for tissue ablation
Hermes Innovations Llc
August 17, 2017 - N°20170231678

Methods of ablating endometrial tissue are disclosed. The methods include providing an ablation device that has a catheter with a hollow shaft through which an ablative agent can travel, a first positioning element, and a second positioning element positioned on the catheter distal to the first positioning element. The second positioning element is a disc shaped wire mesh and has ...
Pme-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and ...
Medical Diagnostic Laboratories, L.l.c.
August 10, 2017 - N°20170226520

Disclosed are methods of attenuating activity of the pme-1 gene. Sirnas or shrnas are used to target against pme-1, thereby reducing the pme-1 mrna. It is disclosed that the sirnas or shrnas targeted against pme-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing sirna or shrna reagents for attenuating the pme-1 gene expression is ...
Endometrial Patent Pack
Download + patent application PDFs
Endometrial Patent Applications
Download + Endometrial-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Endometrial-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for treatment of primary hormone resistant endometrial and breast cancers
Lipoxen Technologies Limited
July 20, 2017 - N°20170202854

The invention provides a method for treatment of primary progesterone receptor-negative (pr−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (pr) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (er−) breast cancer, comprising administering (i) cridanimod or a salt or an ester ...
Method for treatment of primary hormone resistant endometrial and breast cancers
Lipoxen Technologies Limited
July 20, 2017 - N°20170202827

The invention provides a method for treatment of primary progesterone receptor-negative (pr−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (pr) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (er−) breast cancer, comprising administering (i) cridanimod or a salt or an ester ...
Compositions and methods for suppressing endometrial proliferation
Repros Therapeutics Inc.
July 06, 2017 - N°20170189421

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (serm) therapy. The instant invention is also relevant to the suppression of ...
Monoclonal antibodies that specifically block biological activity of a tumor antigen
Morphotek, Inc.
June 29, 2017 - N°20170184603

This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (fr-α). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“fr-α”), ...
Human androgen receptor dna-binding doman (dbd) compounds as therapeutics and methods for their use
The University Of British Columbia
June 29, 2017 - N°20170183319

A compound having the structure of formula i, wherein a is a substituted or unsubstituted aryl or heteroaryl group, d is a substituted or unsubstituted 5- or 6-membered heteroaryl or heterocyclyl group and e is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ...
Anti-folate receptor alpha antibodies and uses thereof
Eisai R&d Management Co., Ltd.
June 15, 2017 - N°20170168078

Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, ...
Nitrogen-containing aromatic heterocyclic compound
Kotobuki Pharmaceutical Co., Ltd.
June 01, 2017 - N°20170152232

As a result of studies on compounds having fgfr inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on fgfr1, fgfr2, and/or fgfr3, particularly, mutant fgfr3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a ...
Endometrial Patent Pack
Download + patent application PDFs
Endometrial Patent Applications
Download + Endometrial-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Endometrial-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Stem cell therapy in endometrial pathologies
Igenomix S.l.
May 11, 2017 - N°20170128492

The invention generally relates to the ability of autologous cd133+ bone marrow stem cells (bmdsc) to induce endometrial regeneration and treat endometrial pathologies such as asherman's syndrome and endometrial atrophy. Methods to induce endometrial regeneration are provided, which comprises administering an effective amount of autologous cd133+ bone marrow derived stem cells (bmdsc) into uterine arteries of a subject in need ...
Vagina evaluation device and uterus evaluation device
Osaka University
May 11, 2017 - N°20170128053

A non-invasive and accurate vagina evaluation device and uterine evaluation devices are provided that measure the receptivity (uterine implantation capacity) of the mother's body to a fertilized egg implanting itself into the uterus. A first vagina evaluation device includes: a main body stretchable and expandable after insertion into a vagina, followed by air injection thereinto; four electrodes brought into contact ...
Method of treating endometriosis
Predictive Therapeutics, Llc
April 27, 2017 - N°20170112881

The present invention is a method of treating or preventing endometriosis by means of administering stem cells to a patient. The stem cells are preferably drawn from umbilical cord tissue and/or umbilical cord blood and are preferably combined with a liquid carrier to form a stem cell solution. In the case of a female patent asymptomatic of endometriosis but ...
Bcl6 expression in eutopic endometrium as a marker for endometriosis and subfertility
Greenville Health System
March 30, 2017 - N°20170089923

Methods for identifying subjects as candidates for embryo implantation are provided. In some embodiments, the methods include providing a sample of endometrium isolated from a subject during the second half of the subject's menstrual cycle and determining whether the subject is a candidate based on the expression of bcl6 in the sample. Also provided are methods for identifying an increased ...
Compositions and methods for modulating the immune system
Bioincept, Llc
March 23, 2017 - N°20170080047

A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted ...
Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
Eisai R&d Management Co., Ltd.
March 16, 2017 - N°20170071903

Methods for treating cancer (e. G., breast cancer, lung cancer, pancreatic cancer, primitive neuroectodermal tumors, lung cancer, ovarian cancer, endometrial cancer, pharyngeal cancer, esophageal cancer, and sarcoma) in a subject (such as an human patient) in need thereof by administering eribulin (e. G., eribulin mesylate, i. E., e7389, halaven) in combination with one or more mammalian target of rapamycin (mtor) ...
Systems and methods for endometrial ablation
Minerva Surgical, Inc.
March 16, 2017 - N°20170071781

An endocervical seal has a sleeve with a passageway for receiving an intrauterine interventional or diagnostic tool. The sleeve has a coaxially disposed outer balloon with a distal portion configured to inflate in a cervical os and a proximal portion configured to inflate in a cervical canal.
Antibodies, antibody drug conjugates and methods of use
Gamamabs Pharma
February 09, 2017 - N°20170035903

This invention relates to antibody drug conjugates (adc), antibody conjugates (ac) and novel antibodies. Particularly, the adc, ac and antibodies disclosed herein specifically bind to the human anti-müllerian hormone type ii receptor (amhr-ii) and can be used to treat and/or identify amhr-ii expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing amhr-ii, such as ...
Loading